Home › Neuroendocrine Carcinoma
Neuroendocrine Carcinoma clinical trials recruiting in the U.S.
16 studies for Neuroendocrine Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY6 studies
- Houston, TX6 studies
- Arlington, VA5 studies
- Los Angeles, CA4 studies
- Dallas, TX4 studies
- Washington, DC4 studies
- Seattle, WA3 studies
- New Haven, CT3 studies
- Columbus, OH3 studies
- Atlanta, GA3 studies
- Denver, CO3 studies
- Grand Rapids, MI3 studies
- Nashville, TN3 studies
- St. Louis, MO3 studies
By state
- California6 studies
- Colorado4 studies
- Connecticut3 studies
- Florida5 studies
- Georgia4 studies
- Louisiana3 studies
- Maryland6 studies
- Michigan3 studies
- Missouri3 studies
- New Jersey4 studies
- New York6 studies
- Ohio4 studies
- Tennessee4 studies
- Texas8 studies
- Virginia5 studies
- Washington4 studies
Recently updated studies
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06406465Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT07509034Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 24, 2026 · NCT05237934Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07278479Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Jul 13, 2026 · NCT05000294A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Jun 15, 2026 · NCT06041516A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT06889493A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.